Sirnaomics Bets On RNAi In China With First IND Approval
Executive Summary
Alan Y Lu, Executive VP of RNAi developer Sirnaomics, talks to Scrip’s Brian Yang about the US-China hybrid's plan to develop anti-fibrosis therapies in both markets.
You may also be interested in...
Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment
Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.
China’s Regulator Has New Head But Will He Advance Further Reforms?
A new commissioner has taken the reins at China's National Medical Products Administration, but the senior CCP official has so far given few clear indications about the changes he might bring.
Hua Medicine's Chen On Product Launch, Bayer Partnership And Reimbursement
Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies.